---
title: "Summit Therapeutics (SMMT) news: going concern and offering"
url: "https://aibio.space/companies/summit-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SMMT going concern, offering and lawsuit news. Summit Therapeutics news for investors: Summit develops ivonescimab, a PD-1 and VEGF bispecific antibody…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Summit's FDA date arrives before its global lung data

Summit is a one-drug company facing its first FDA decision on Nov 14 with a survival result that has improved but has not been formally significant. The larger question is whether the global first-line trials replicate the China data. Until then the company funds itself by selling stock, and its latest 10-Q says that is not yet enough for twelve months.

Read the full desk view

aibio.space Investor Rank · Opinion

**2** /10 Most negative view

A one-drug company with going concern language, an FDA application whose survival result is not formally significant and a HARMONi-3 interim that missed its bar.

- **Technology**: 1/2

- **Odds**: 0/2

- **Balance sheet**: 0/2

- **Risk**: 0/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Strong in China, unproven in the West.** Ivonescimab beat tislelizumab on survival in Akeso's HARMONi-6 trial (hazard ratio 0.66), but global data are mixed.

- **Odds**: **Hard to call.** The HARMONi survival hazard ratio is 0.76 without a disclosed confidence interval, and the FDA reportedly asked for significant survival.

- **Balance sheet**: **Funded by stock sales.** $690.7 million at June 30, a $380 million ATM program, and going concern language in the 10-Q.

- **Main risk**: **Western lung data.** The HARMONi-3 squamous interim PFS missed its higher bar, and the final analysis is due in the second half of 2026.

- **Watch next**: **Nov 14, 2026.** The FDA goal date for the first U.S. ivonescimab application.

## Top news on Summit

1. 2026-07-23 Distress [Summit files $380 million stock program as 10-Q flags going concern doubt](https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/) Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM.
2. 2026-07-23 Legal [Summit Therapeutics derivative suit over $520 million Duggan notes ends in voluntary dismissal](https://aibio.space/news/summit-therapeutics-derivative-suit-520-million-duggan-notes-ends/) Rainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026.

## Dates

**Nov 14, 2026**
FDA goal date for ivonescimab BLA in EGFR-mutated non-squamous NSCLC [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2026-2026.pdf)

**Second half of 2026**
HARMONi-3 squamous cohort final PFS analysis and interim overall survival [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf)

**First half of 2027**
HARMONi-3 non-squamous cohort PFS data and a further squamous OS interim analysis [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf)

**By mid-2027**
Data from the Arcus casdatifan combination in renal cell carcinoma [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf)

## The money

$690.7 million in cash and short-term investments at June 30, 2026 (down from $713.4 million at Dec 31, 2025), plus $68.4 million raised through the ATM after June. The 10-Q contains going concern language; no explicit runway guidance. [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf)

## Risks on the record

- The 10-Q says cash and short-term investments are not sufficient to fund planned operations for at least one year, raising substantial doubt about the company's ability to continue as a going concern. [Source](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm)
- The HARMONi survival result was not statistically significant at the primary analysis (hazard ratio 0.79, p=0.057), and Fierce Pharma reports the FDA had asked for a significant overall survival result. [Source](https://www.fiercepharma.com/pharma/summit-therapeutics-updates-ivonescimab-survival-data-ahead-fda-decision-date)
- The HARMONi-3 squamous interim PFS analysis did not meet its significance threshold in April 2026. [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2026-2026.pdf)

## Questions investors ask

### What is aibio.space's Investor Rank for Summit Therapeutics?

2 out of 10, our most negative view. A one-drug company with going concern language, an FDA application whose survival result is not formally significant and a HARMONi-3 interim that missed its bar. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### When is the FDA decision date for Summit's ivonescimab?

The FDA set a PDUFA goal date of Nov 14, 2026 for ivonescimab plus chemotherapy in EGFR-mutated, non-squamous NSCLC after prior EGFR TKI therapy. Fierce Pharma reported that the July survival update may extend the review by three months. [Source](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000058/a2026_prx0722xharmonidat.htm)

### What did the HARMONi trial show for overall survival?

The overall survival hazard ratio was 0.79 at the April 2025 primary analysis (p=0.057), 0.78 in September 2025, and 0.76 in June 2026. Confidence intervals for the latest cut have not been disclosed. [Source](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000058/a2026_prx0722xharmonidat.htm)

### How much cash does Summit Therapeutics have?

Summit reported $690.7 million in cash and short-term investments at June 30, 2026. It raised another $68.4 million through its ATM after June and filed a new program of up to $380 million on July 23. [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf)

### What happened in the HARMONi-3 interim analysis?

On April 30, 2026 Summit said an early interim PFS analysis in the squamous cohort did not meet the higher significance bar. The monitoring committee recommended continuing, and final PFS is expected in the second half of 2026. [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2026-2026.pdf)

### Does Summit Therapeutics have a going concern warning?

Yes. Its 10-Q for the quarter ended June 30, 2026 says cash and short-term investments are not sufficient to fund planned operations for at least one year and that this raises substantial doubt about its ability to continue as a going concern. [Source](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm)

### What is the latest Summit Therapeutics (SMMT) stock news?

Our latest story on Summit Therapeutics, dated Jul 23, 2026: "Summit files $380 million stock program as 10-Q flags going concern doubt". Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM. [Source](https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/)

### How long will Summit Therapeutics's cash last?

From our story of Jul 23, 2026: The 10-Q contains going concern language. [Source](https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/)

### Is Summit Therapeutics in financial distress?

Our latest distress story, dated Jul 23, 2026: "Summit files $380 million stock program as 10-Q flags going concern doubt". Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM. [Source](https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/)

### Is Summit Therapeutics facing a lawsuit?

Our latest legal story, dated Jul 23, 2026: "Summit Therapeutics derivative suit over $520 million Duggan notes ends in voluntary dismissal". Rainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/summit-therapeutics-derivative-suit-520-million-duggan-notes-ends/)

### What is Summit Therapeutics's market cap?

We do not publish live share prices. In its annual report, Summit Therapeutics Inc. put the market value of shares held by non-affiliates (public float) at $2.48 billion as of Jun 30, 2025. Source

### Is Summit Therapeutics a smaller reporting company?

SEC records list Summit Therapeutics Inc.'s filer category as: Large accelerated filer. Source

### Where is Summit Therapeutics headquartered?

SEC records list its business address as 601 BRICKELL KEY DRIVE, MIAMI, FL, 33131. Source

### When does Summit Therapeutics's fiscal year end?

Summit Therapeutics Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Summit Therapeutics last file with the SEC?

Its most recent filing in our record is a DEF 14A filed 2026-10-19. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1599298/000119312526424642/d126889ddef14a.htm)

## Legal and investor matters

Checked against Summit Therapeutics filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

1. 2026-09-28 Financing Summit agrees to sell $2.0 billion of convertible preferred stock to AstraZeneca unit Summit said in an 8-K that on September 28, 2026 it signed a securities purchase agreement with AstraZeneca Holdings B.V. for 108,955.3686 shares of Class A Convertible Preferred Stock at $18,356.14 per share, for gross proceeds of $2.0 billion. Each share converts into 1,000 common shares. Closing was expected within five business days, subject to conditions. Summit has called a November 4, 2026 special meeting to vote on raising authorized common shares to 2,000,000,000. [Summit 8-K filed 2026-09-29](https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892d8k.htm)
2. 2026-07-23 Financing Summit 10-Q cites going concern doubt and a new $380 million at-the-market program In its 10-Q filed July 23, 2026, Summit stated that its conditions raise substantial doubt about its ability to continue as a going concern. The same day it entered a distribution agreement with J.P. Morgan Securities LLC to sell common stock with an aggregate offering price of up to $380,000,000 in at-the-market transactions. The 8-K says the company is not obligated to sell any shares under the agreement. [Summit 10-Q filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm)
3. 2026-06-10 Financing Summit withdraws proposed underwritten public offering citing market conditions Summit announced in an 8-K that effective June 10, 2026 it withdrew its previously announced proposed underwritten public offering of securities due to market conditions. The prospectus supplement dated June 2026 had described an offering of $500.0 million of common stock. The company said no securities will be sold under the proposed offering. [Summit 8-K filed 2026-06-11](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000052/smmt-20260610.htm)
4. 2026-05-27 Derivative suit Delaware derivative suit over Summit's December 2022 notes is dismissed by stipulation Summit reported in its 10-Q that on May 27, 2026 the plaintiff and defendants stipulated to voluntary dismissal of the derivative lawsuit filed by Rainaldi Revocable Trust in the Delaware Court of Chancery. The dismissal was with prejudice as to the plaintiff and without prejudice as to any other stockholder, and the court approved it the same day. The complaint concerned the December 2022 notes issued to Mr. Duggan and Dr. Zanganeh. Delaware Court of Chancery · Status: dismissed [Summit 10-Q filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm)
5. 2025-10-21 Financing Summit sells about $500 million of common stock in private placement at $18.74 Summit said in an 8-K that on October 21, 2025 it entered into securities purchase agreements for a private placement of an aggregate of 26,682,846 common shares at $18.74 per share, for gross proceeds of approximately $500.0 million. The filing states that Mr. Duggan, Dr. Zanganeh, Mr. Soni, Mr. Anand and certain employees participated, buying 14,514,402 shares in total. Akeso, Inc. also participated as an investor. [Summit 8-K filed 2025-10-22](https://www.sec.gov/Archives/edgar/data/1599298/000119312525245790/d274712d8k.htm)
6. 2025-08-11 Financing Summit adds $360 million to at-the-market program with J.P. Morgan Summit disclosed in an 8-K that on August 11, 2025 it amended its May 13, 2024 distribution agreement with J.P. Morgan Securities LLC to increase the aggregate offering price of common stock that may be sold by up to an additional $360,000,000. The filing says approximately $45.8 million remained available under the earlier May 2024 prospectus supplement as of that date. [Summit 8-K filed 2025-08-11](https://www.sec.gov/Archives/edgar/data/1599298/000119312525178022/d56029d8k.htm)
7. 2025-06-18 Litigation Third party files European opposition against ivonescimab patent EP3882275B1 Summit reported in its 10-Q that on June 18, 2025 an unknown third party filed a notice of opposition at the European Patent Office against the in-licensed EP3882275B1 patent covering ivonescimab. The notice primarily asserts that the patent lacks inventive step. Summit and its partner Akeso filed a response on January 2, 2026, and the 10-Q filed July 23, 2026 lists further filings through June 24, 2026. European Patent Office, Opposition Division · Status: pending [Summit 10-Q filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm)
8. 2025-03-17 Derivative suit Stockholder files derivative suit over Summit's December 2022 notes in Delaware Summit reported in its 10-Q that on March 17, 2025 Rainaldi Revocable Trust, a purported stockholder, filed a derivative lawsuit in the Delaware Court of Chancery against certain current and former directors, naming the company as nominal defendant. The suit concerns the December 2022 notes with Mr. Duggan and Dr. Zanganeh. It asserts claims for breach of fiduciary duty and unjust enrichment and seeks unspecified damages and rescission of certain shares. Delaware Court of Chancery · Status: filed [Summit 10-Q filed 2025-05-01](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000089/smmt-20250331.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Ivonescimab + chemotherapy (HARMONi) | EGFR-mutated non-squamous NSCLC after EGFR TKI | BLA under FDA review, PDUFA Nov 14, 2026 [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2026-2026.pdf) |
| Ivonescimab + chemotherapy (HARMONi-3) | First-line NSCLC, squamous and non-squamous, vs pembrolizumab + chemo | Phase 3, enrollment complete, PFS data 2H 2026 (squamous) and 1H 2027 (non-squamous) [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) |
| Ivonescimab monotherapy (HARMONi-7) | First-line metastatic NSCLC with high PD-L1, vs pembrolizumab | Phase 3, enrolling [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) |
| Ivonescimab + chemotherapy (HARMONi-GI3) | First-line metastatic colorectal cancer, vs bevacizumab + chemo | Phase 3, enrolling since Q4 2025 [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2026-2026.pdf) |
| Ivonescimab combinations | Solid tumors with GSK, Revolution Medicines, Arcus and GORTEC | Early studies and a GORTEC phase 3 (ILLUMINE) in head and neck cancer [Source](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Summit's survival story reads stronger in releases than in its own 10-Q

Summit's releases describe the HARMONi survival data as consistent and confidence building ahead of the Nov 14, 2026 FDA date. The 10-Q adds that the FDA said a statistically significant survival benefit is necessary in this setting, which the primary analysis did not reach, and the later figures carry only nominal p values. The going concern language in the 10-Q was absent from the earnings release, though the $2 billion AstraZeneca investment announced in September changes the cash picture.

1. Press release vs filing · weight high FDA's survival bar is in the 10-Q, not the release **The company said:** "these data reinforce our confidence in the HARMONi results as we work toward the potential approval of ivonescimab in the U.S." [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/a2026_prx0915xharmoniltf.htm) **The record says:** The 10-Q states: "The FDA noted that a statistically significant OS benefit is necessary to support marketing authorization in this setting and the PFS results from this study may not be sufficient to support marketing authorization." It also says the primary OS analysis showed a positive trend "without achieving a statistically significant benefit with a hazard ratio of 0.79" (p=0.057). [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm) **Our view:** The Sept. 15 release names the Nov 14 PDUFA date but does not repeat the FDA's stated requirement. That requirement is the main test the application faces, and the release's upbeat framing reads differently once it is known.
2. Science · weight high Later survival looks carry nominal p values, and the western subgroup still crosses 1 **The company said:** "With longer follow-up, western patients replicated the survival improvement seen in Asian patients, further reinforcing the regional consistency of the efficacy results observed in the global HARMONi study." [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/a2026_prx0915xharmoniltf.htm) **The record says:** The same release's table gives the June 2026 global hazard ratio as 0.76 with "nominal p=0.0151" and the western subgroup hazard ratio as 0.76 with a 95% confidence interval of 0.52 to 1.10 (n=83 vs 82). Asian patient data were locked at April 2025. ClinicalTrials.gov lists OS in the ITT population as a primary outcome alongside PFS, with primary completion on April 12, 2025. [source](https://clinicaltrials.gov/study/NCT06396065) **Our view:** The protocol's OS test was the April 2025 analysis, which missed. Extra data cuts with nominal p values are supportive at best, and a western subgroup interval that includes 1 is not the same as replication.
3. Press release vs filing · weight medium Earnings release led with cash; the 10-Q states going concern doubt in its notes, MD&A and risk factors **The company said:** "Summit Closes Second Quarter with $690.7 Million in Cash and Investments" [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/a2026_prx0723xq22026earn.htm) **The record says:** The 10-Q filed the same day says: "These conditions raise substantial doubt about our ability to continue as a going concern." On Sept. 28, 2026 Summit announced a $2.0 billion AstraZeneca investment in convertible preferred stock; the 8-K says closing was expected "within five business days" and conversion depends on HSR clearance and a charter amendment raising authorized shares. [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm) **Our view:** The July release did not mention the going concern language. The AstraZeneca money, if closed, should address it, and the next 10-Q will show whether the language is removed.
4. Science · weight medium Most clean survival wins come from China-only Akeso trials **The company said:** "including recent positive results from HARMONi-2 and HARMONi-GI1 in biliary tract cancer" [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/a2026_prx0915xharmoniltf.htm) **The record says:** The release itself says HARMONi-2 "is a single-region, multi-center Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso" and that its OS result came from an interim analysis of "a secondary endpoint". The 10-Q says the global HARMONi-3 squamous interim PFS look faced "a meaningfully higher bar" and the iDMC "recommended that the study continue as planned". [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm) **Our view:** Summit discloses the China-only design plainly, which is fair. The global HARMONi-3 study has not yet reported a win, so the China results remain the main support for broader use.
5. Legal and disclosure record · weight low Derivative suit over insider notes was dismissed in May 2026 **The record says:** Legal Proceedings in the 10-Q: on March 17, 2025, Rainaldi Revocable Trust filed a derivative lawsuit in the Delaware Court of Chancery over the December 2022 notes from Mr. Duggan and Dr. Zanganeh. "On May 27, 2026, Plaintiff and the Defendants stipulated to voluntary dismissal of Plaintiff's claims with prejudice as to Plaintiff and without prejudice as to any other stockholder of the Company". No securities class action or enforcement action is disclosed. [source](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm) **Our view:** The one disclosed suit is closed as to that plaintiff. The 10-Q describes the dismissal as without prejudice as to any other stockholder.

Documents we compared

- [Press release: updated HARMONi data at WCLC 2026 (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/a2026_prx0915xharmoniltf.htm) 2026-09-15
- [Press release: AstraZeneca $2 billion equity investment (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892dex991.htm) 2026-09-28
- [Form 8-K: AstraZeneca private placement terms](https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892d8k.htm) 2026-09-29
- [Press release: second quarter 2026 results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/a2026_prx0723xq22026earn.htm) 2026-07-23
- [Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm) 2026-07-23
- [ClinicalTrials.gov NCT06396065 (HARMONi)](https://clinicaltrials.gov/study/NCT06396065) 2026-07-28

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SMMT on TradingView](https://www.tradingview.com/symbols/NASDAQ-SMMT/).

## SEC filings and registration

- **SEC name**: Summit Therapeutics Inc.

- **CIK**: 1599298

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: SMMT (Nasdaq)

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 601 BRICKELL KEY DRIVE, MIAMI, FL, 33131

- **Phone**: 305-203-2034

- **Shares outstanding**: 797,749,602 as of 2026-07-17 (10-Q filed 2026-07-23)

- **Former names**: Summit Therapeutics plc; Summit Corp plc

### Recent filings (8-K and 6-K are the company's own announcements)

- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1599298/000119312526424642/d126889ddef14a.htm) filed 2026-10-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892d8k.htm) filed 2026-09-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/smmt-20260915.htm) filed 2026-09-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/smmt-20260913.htm) filed 2026-09-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/smmt-20260902.htm) filed 2026-09-03
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/smmt-20260825.htm) filed 2026-08-26
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/smmt-20260805.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1599298/000119312526314214/d143170d8k.htm) filed 2026-07-23

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001599298), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/summit-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Summit Therapeutics (SMMT) news: going concern and offering", 2026-10-31, https://aibio.space/companies/summit-therapeutics/